Adjunct Professor, Pharmaceutics and Pharmaceutical Chemistry
Education History
| Graduate Training |
University of Massachusetts |
MBA |
|---|---|---|
|
University of Texas Health Science Center |
Fellow | |
| Residency |
Michael Reese Hospital |
Resident |
|
Michael Reese Hospital |
Intern | |
| Residency |
Post Graduate Institute of Medical Education and Research |
Junior Resident |
|
University of Delhi Hospital |
Intern | |
| Professional Medical |
University of Delhi |
MD |
|
Sardar Patel Vidyalaya |
AISSC |
Selected Publications
Journal Article
- Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 29(6), 1267-78.
- Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol, 75(1), 87-95.
- Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 28(11), 2155-64.
- Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther, 13(10), 2315-27.
- Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer, 85(3), 429-34.
- Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res, 20(17), 4584-97.
- Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014). Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget, 5(14), 5637-50.
- Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA (2014). Colon cancer, version 3.2014. J Natl Compr Canc Netw, 12(7), 1028-59.
- Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade JL (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 73(6), 1241-52.
- Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther, 13(5), 1142-54.
- Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014). Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370(13), 1189-97.
- Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9.
- Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, ODay SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ (2014). Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol, 32(2), 129-60.
Abstract
- Shaw AT, Camidge DR, Felip E, Sharma S, Tan DSW, Kim DW, De Pas T, Vansteenkiste JF, Santor A, Liu G, Chow L, Goldwasser M, Lau Y, Boral AL, Mehra R (2012). Results of the first-in-human Phase I study of the ALK inhibitor LDK378 in advanced malignancies [Abstract]. Oral presentation ESMO Congress.
- Wade JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels J, Conkright WA, Sharma S, Soetekouw P, Yachnin J, Sengelv L, van Veldhuizen P, Agarwala SS, Quyen Nguyen TX, Chadjaa M, Maison-Blanche P (2012). A QTc study of cabazitaxel in patients with advanced solid tumors [Abstract]. Poster ASCO Genitourinary Cancers Symposium.
Patent
- Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S (2016). Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.
- Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2015). “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.
- Vankayalapati H, Sorna V, Warner S, Stephens B, Bearss D, Sharma S (2015). Substituted (E)-N'-(1-Phenylethylidene)Benzohydrazide Analogs as Histone Demethylase Inhibitors”. U.S. Patent No. 8,987,335. Washington, D.C.:U.S. Patent and Trademark Office.
- Bearss D, Vankayalapati H, Mollard A, Warner S, Sharma S (2014). Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase. U.S. Patent No. 8,901,120. Washington, D.C.:U.S. Patent and Trademark Office.
- Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2012). “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.